Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

PURPOSE: We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanc...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., Rubinstein, Larry, Parchment, Ralph E., Phillips, Lawrence R., Ji, Jiuping, Monks, Anne, Low, Jennifer A., Chen, Alice, Murgo, Anthony J., Collins, Jerry, Steinberg, Seth M., Eliopoulos, Helen, Giranda, Vincent L., Gordon, Gary, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E., Doroshow, James H.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2009
Θέματα:
Original Reports
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2739635/
https://ncbi.nlm.nih.gov/pubmed/19364967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.7681
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια